Generic Pharmaceutical Manufacturers
Organizations developing generic medicinal products that require comparative bioequivalence evidence.
Bioequivalence & Bioavailability Partner Access
Bioequivalence Study Partner Access
Confidential access to an independent specialist organization for the assessment, planning and execution of bioequivalence, bioavailability and pharmacokinetic study requirements.
Confidential preliminary review
NDA-based discussions available
Independent specialist provider
Independent partner model
Specialist bioequivalence capabilities through a confidential professional collaboration
Bioequivalence and bioavailability studies require dedicated clinical infrastructure, validated bioanalytical capabilities, pharmacokinetic expertise and robust quality systems.
GxP Auditing & Advisory facilitates qualified introductions between pharmaceutical organizations and an independent specialist provider capable of assessing and supporting relevant BA/BE study requirements.
Important clarification:
GxP Auditing & Advisory does not directly conduct bioequivalence or
bioavailability studies. Our role is to assess the preliminary request,
facilitate a confidential introduction and, where required, provide
separately scoped quality and compliance advisory support.
Who this is for
Designed for pharmaceutical organizations seeking specialized BA/BE study support
This dedicated access page supports organizations seeking a qualified specialist contact for technical assessment and potential study execution.
Product Developers & Sponsors
Sponsors developing reformulated, hybrid or modified pharmaceutical products requiring clinical and pharmacokinetic evaluation.
Marketing Authorization Applicants
Applicants seeking an appropriate specialist organization for regulatory submission-related BA/BE requirements.
International Life Sciences Companies
International organizations seeking access to a qualified regional clinical and bioanalytical study partner.
Portfolio & Pipeline Teams
Development teams evaluating feasibility, timelines and outsourcing options across multiple pharmaceutical products.
Organizations Requiring Vendor Oversight
Sponsors that also require independent vendor qualification, quality agreement review or ongoing QA oversight.
Potential study requirements
Projects that may be suitable for specialist partner assessment
Availability, technical feasibility, regulatory suitability and timing are determined independently by the specialist provider following detailed review.
Clinical & Pharmacokinetic Study Support
- Comparative bioequivalence studies
- Bioavailability studies
- Pharmacokinetic studies
- Food-effect studies
- Drug–drug interaction studies
- Clinical study execution involving healthy volunteers
Bioanalytical & Documentation Support
- Bioanalytical method development and validation
- Biological sample analysis
- Pharmacokinetic and statistical evaluation
- Clinical and bioanalytical study documentation
- Study reporting support
- Technical feasibility and timeline assessment
Why use coordinated partner access?
A more structured route to an appropriate specialist contact
Initial coordination helps establish relevance, confidentiality and basic project alignment before detailed technical discussions begin.
Efficient Access
Reach an appropriate specialist contact without publishing or circulating confidential partner details.
Preliminary Alignment
Clarify the study type, product profile, intended market and expected timeline before detailed technical discussions.
Optional QA Support
Add independent vendor qualification, quality agreement review, auditing or sponsor oversight where required.
How it works
A structured and confidential introduction process
The process is designed to qualify the request before disclosing the identity and direct contact information of the independent specialist provider.
Confidential Initial Inquiry
Provide a high-level overview of the product, intended market, proposed study type and expected timeline.
Preliminary Suitability Review
We assess whether the request appears suitable for introduction to the independent specialist provider.
NDA, Where Required
Suitable confidentiality arrangements may be established before detailed technical information is exchanged.
Qualified Partner Introduction
Where appropriate, we facilitate direct communication with the relevant specialist contact.
Technical & Commercial Assessment
The independent provider evaluates feasibility, study design, documentation requirements, timing and commercial scope.
Independent Engagement
Technical proposals, contracts and study execution are agreed directly between the sponsor and specialist provider.
Optional independent support
Quality assurance and compliance services can be scoped separately
GxP Auditing & Advisory may provide independent advisory, auditing or oversight support alongside the specialist engagement.
Vendor Qualification
- CRO and specialist provider qualification
- Risk-based vendor assessment
- Quality agreement review
- Vendor oversight frameworks
GCP, GLP & Data Integrity
- GCP audits
- GLP and laboratory audits
- Data integrity assessments
- Documentation and traceability review
Inspection & CAPA Support
- CAPA review and remediation support
- Study documentation readiness
- Audit and inspection preparation
- CAPA effectiveness verification
Confidentiality & controlled disclosure
Partner details are shared only after preliminary qualification
This approach protects the professional relationship, preserves confidentiality and helps ensure that introductions are relevant to the proposed project.
Confidential Initial Review
Initial inquiries are reviewed confidentially. Only high-level information should be submitted before appropriate confidentiality arrangements are established.
Controlled Partner Disclosure
The identity and direct contact details of the specialist provider are disclosed only after preliminary review and confirmation that the opportunity is relevant and appropriate for introduction.
Important notice:
GxP Auditing & Advisory does not act as the clinical study site,
bioanalytical laboratory, study sponsor or contracting provider for the
execution of bioequivalence or bioavailability studies. Technical
feasibility, regulatory responsibilities, commercial terms, study conduct
and final deliverables remain the responsibility of the independent
specialist provider and the contracting sponsor. Any auditing, quality
assurance or advisory services provided by GxP Auditing & Advisory are
scoped and contracted separately.
Confidential partner introduction
Discuss Your Bioequivalence Study Requirements
Provide a high-level overview of your product, intended regulatory market, anticipated study type and expected timeline.
We will review the request confidentially and, where appropriate, facilitate an introduction to the independent specialist provider.
- Confidential preliminary review
- NDA-based discussions available where required
- Partner details disclosed only after qualification
- Optional independent QA and vendor oversight support